An open, non-comparative, multicenter study on the sexual function improvement following treatment with alfuzosin in patients with benign prostate hyperplasia
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs Alfuzosin (Primary)
- Indications Benign prostatic hyperplasia
- Focus Therapeutic Use
- Sponsors Handok Inc
- 28 Nov 2007 Status changed from in progress to completed.
- 11 Oct 2007 Handok Pharmaceuticals reported as trial affiliate.
- 11 Oct 2007 Handok Pharmaceuticals reported as trial sponsor.